Ventyx Biosciences, Inc. Cashflow Statement

Ask AI

Overview Financial Statements SEC Filings Executives News Red Flags Capital Raising Ownership Insider Transactions Congressional Trades

Financial Statements

Income Statement Balance Sheet Cashflow Statement

Consolidated Statements of Cash Flows

In millions of USD, except per-share amounts

	FY2024 12 months to Dec 31, 2024	FY2023 12 months to Dec 31, 2023	FY2022 12 months to Dec 31, 2022	FY2021 12 months to Dec 31, 2021
Cash flows from operating activities
Net loss
Adjustments to reconcile net loss to net cash used in operating activities
Depreciation
Loss on disposal of fixed assets
Gain on lease termination
Loss on impairment
Amortization of right-of-use assets - operating
Stock-based compensation
Accretion of marketable securities, net
Non-cash interest - related party
Change in fair value of notes and derivative - related party
Change in fair value of Series A tranche liability
Acquired in-process research and development

Changes in operating assets and liabilities
Prepaid expenses and other assets
Operating lease liabilities
Accounts payable
Accrued expenses
Net cash used in operating activities
Cash flows from investing activities
Acquisition of Oppilan and Zomagen, net of cash
Purchases of marketable securities, available-for-sale
Proceeds from maturities of marketable securities, available-for-sale
Purchases of property and equipment
Net cash (used in) provided by investing activities

Cash flows from financing activities
Proceeds from issuance of common stock from at-the-market offering, net of commissions and offering expenses
Proceeds from issuance of common stock from private placement, net of offering costs
Proceeds from issuance of Series A and Series B convertible preferred stock, net of offering costs
Proceeds from issuance of common stock in initial public offering, net of underwriting discounts, commissions and offering expenses
Proceeds from issuance of Series A non-voting convertible preferred stock from private placement, net of offering costs
Proceeds from exercise of stock options
Proceeds from issuance of common stock under employee stock purchase plan
Proceeds from issuance of SAFE notes, net
Net cash provided by financing activities

Effect of exchange rates on cash
Effect of exchange rates on cash, cash equivalents and restricted cash
Net decrease in cash, cash equivalents and restricted cash
Cash, cash equivalents and restricted cash, beginning of year
Cash, cash equivalents and restricted cash, end of year
Taxes paid
Supplemental disclosure for noncash activities
Conversion of Series A, A-1 and B preferred stock to common stock in connection with initial public offering
Conversion of promissory and SAFE notes - related party
Stock issued for the acquisitions of Oppilan and Zomagen
Unrealized loss on marketable securities
Unpaid private placement offering costs
Unpaid costs associated with the issuance of Series A non-voting convertible preferred stock from private placement
Purchases of property and equipment included in accounts payable and accrued expenses

Comments